Evotec offers unique proteomics services to address key issues in drug and biomarker discovery. The Company continuously advances its capabilities in mass spectrometry-based proteomics to ensure unrivalled comprehensiveness and data quality when analysing cells, animal models and patient samples.
The Company’s offering includes:
Highly optimised experimental strategies tailored to different proteomics applications and project needs
Industry-leading capabilities in high-end quantitative mass spectrometry
Experience and infrastructure to analyse the enormous amounts of data generated in large-scale proteomics projects
Advanced statistics and bioinformatics for systems-wide data analysis
In-depth data interpretation to extract relevant drug target and mode-of-action information from proteomics experiments
Extensive track record to deliver high-quality results within agreed timelines
Evotec’s chemical proteomics technologies such as Cellular Target Profiling® reveal cellular drug targets and selectivity in an unbiased manner. Other Evotec proteomics technologies record protein modification and expression on a proteome-wide scale for drug mode-of-action analysis or biomarker discovery efforts. Thus, the Company’s platform offers highly innovative solutions that can be leveraged across the entire drug discovery and development pipeline.